CYP46A1 and neurodegenerative disease: Decreases of CYP46A1 levels in patients with severe neurodegenerative diseases, like AD, HD, and Scas, and the phenotypic impairment observed in Cyp46a1–/– mice, prompted studies of potential detrimental consequences of CYP46A1 inhibition in adult mice.